Headway
Headway's platform, the largest US mental health network, connects patients with therapists who accept insurance, powering over 600,000 monthly appointments.
Secondary Market Price
Secondary Market Price
Secondary Market Price Chart
Secondary market prices shown here are a limited preview. Create a free account to access real-time secondary market prices.
Sign up to Unlock the Latest DataProspect Projected Future Headway Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Headway's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Headway is a mental health technology company building a new care system by making it easier for patients to connect with therapists who accept their insurance. The company operates a software-enabled network that helps providers scale their practices and currently powers over 600,000 appointments per month. Headway was founded in 2017 after co-founders Andrew Adams and Jake Sussman struggled to find therapists in New York City who were in-network. They, along with Kevin Chan and Dan Ross, established the company to address this gap, creating a platform that simplifies the process for both patients seeking affordable care and therapists looking to grow their practices without the administrative burden of dealing with insurance payers.
Looking forward, Headway is backed by over $325 million in funding from prominent investors including Andreessen Horowitz, GV, and Spark Capital. The company is focused on scaling its vision of accessible mental healthcare while also working to define and improve the quality of that care. A significant recent step in this direction was the appointment of Dr. Neha Chaudhary, a practicing psychiatrist, as the company's Chief Medical Officer. Her role is centered on supporting providers with better tools and data, partnering with clinicians to establish quality benchmarks, and unlocking insights to improve patient outcomes. This focus on clinical quality, combined with recent accolades like being named one of America's Best Online Platforms of 2025 by Newsweek, signals the company's ambition to set new standards in the mental health industry.
- Andreessen Horowitz
- Accel
- GV
- Thrive Capital
- Spark
- GFC Capital
- Global Founders Capital
- IA Ventures
- Co-Founder, CEO Andrew Adams
- Co-Founder, Daniel Ross
- Co-Founder, Kevin Chan
- Co-Founder, Jake Sussman
Peer Group Comparison
Vs Peer Group of >$4B Startups
How Headway Measures Up
To help you manage your Headway equity, Prospect has run the company through our machine learning model.
Prospect Rating
2x
Our rating indicates Headway could be worth at least 2x its current value in four years. For employees with equity, this rating points to a moderate potential for growth in their stock value, balanced by a lower risk profile.
Exit Risk
Low Risk
We rate Headway as Low Risk because its backing by top investors, rapid scaling, and successful fundraising since the market downturn indicate a lower likelihood of it failing to reach a liquidity event for employees compared to other startups.
Funding Stage
Funding
As Headway is currently in its funding stage, it's actively securing capital to fuel significant growth, which means more opportunities for new team members. For you, this translates to a chance to join a rapidly scaling company where your contributions can have a direct and meaningful impact.
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Headway worth joining?
Headway is a well-funded company backed by top investors, but it faces significant competition and challenges with product differentiation. Platforms like Prospect use VC-grade data to help you evaluate such opportunities and make an informed career decision.
What should I do with my Headway stock?
Managing equity in a private company like Headway involves complex tax and timing decisions that can significantly impact your financial outcome. You can use specialized equity tools to model different scenarios and create an optimal strategy for your stock options or RSUs.
Can you sell Headway stock?
Since Headway is a private company, its stock is not traded on public exchanges like the NYSE or NASDAQ. However, employees and early investors may be able to sell their shares through secondary markets, which platforms like Prospect can help you navigate.
How can I find the value of my Headway stock?
A private company's stock value is formally determined by a 409A valuation, often influenced by the price set during its most recent funding round. To understand its potential future worth, you can use data-driven platforms that model startup equity value based on factors like growth metrics and investor quality.
What is Headway's equity worth?
As a company, Headway's latest valuation is $2.3 billion, which provides a benchmark for its overall equity value. The worth of your specific equity grant depends on various factors, which can be analyzed using an equity calculator to project potential returns.
What is Headway's stock ticker symbol?
Headway does not have a stock ticker symbol because it is a private company and its shares are not publicly traded. Ticker symbols are only assigned to companies when they list on a public stock exchange.
Can I buy or sell Headway stock?
Headway stock is not available for the general public to buy on stock exchanges, though existing shareholders may be able to sell shares on secondary markets. Platforms like Prospect provide tools and data to help stockholders understand their options for liquidity in private companies.
What is the criteria to buy or invest in Headway stock?
Investment in a late-stage private company like Headway is typically limited to accredited investors and venture capital firms participating in official funding rounds. Opportunities for the general public to invest are generally not available until the company pursues an Initial Public Offering (IPO).
